ITK抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using ITK mouse mAb against Jurkat cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Jurkat cells using ITK mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using ITK mouse mAb (blue) and negative control (red).    

  
  

**Background of ITK Antibodies**

The Interleukin-2-inducible T-cell kinase (ITK) is a non-receptor tyrosine kinase belonging to the Tec kinase family, primarily expressed in T lymphocytes, natural killer (NK) cells, and mast cells. It plays a critical role in T-cell receptor (TCR) signaling, regulating T-cell activation, differentiation, and cytokine production. ITK is activated following TCR engagement, mediating downstream signaling through phosphorylation of phospholipase C-gamma 1 (PLCγ1) and modulation of calcium flux, NFAT, and MAP kinase pathways. Its involvement in immune regulation makes it a target for studying autoimmune diseases, allergic responses, and cancer.

ITK antibodies are tools designed to detect, inhibit, or modulate ITK activity in research and therapeutic contexts. In research, they help elucidate ITK's role in immune cell signaling and its interaction with pathways linked to inflammation or oncogenesis. Therapeutically, ITK inhibitors, including monoclonal antibodies, are explored for conditions like asthma, rheumatoid arthritis, and T-cell lymphomas, aiming to suppress aberrant immune responses or malignant cell proliferation. Challenges include ensuring specificity to avoid off-target effects and optimizing pharmacokinetics. Despite these hurdles, ITK remains a promising target for immunomodulation, with ongoing studies advancing its translational potential.